Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. - Wikidata - awgldk - TriplyDB

Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors.

Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors.

http://www.wikidata.org/entity/Q37259430

about

Podoplanin associates with adverse postoperative prognosis of patients with clear cell renal cell carcinoma The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics Identification of novel tumor-associated cell surface sialoglycoproteins in human glioblastoma tumors using quantitative proteomics A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.Suppression of Aggrus/podoplanin-induced platelet aggregation and pulmonary metastasis by a single-chain antibody variable region fragment The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis Serines in the intracellular tail of podoplanin (PDPN) regulate cell motility.Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas.Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN.Immunotoxin Therapy for Lung Cancer.EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery.Podoplanin--a novel marker in oral carcinogenesis.Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms.Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin.MiR-449a exerts tumor-suppressive functions in human glioblastoma by targeting Myc-associated zinc-finger protein.Podoplanin: a marker for reactive gliosis in gliomas and brain injury.Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism.Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.Targeting Malignant Brain Tumors with Antibodies.Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.Plasma soluble podoplanin is a novel marker for the diagnosis of tumor occurrence and metastasis.A Real-Time Near-Infrared Fluorescence Imaging Method for the Detection of Oral Cancers in Mice Using an Indocyanine Green-Labeled Podoplanin Antibody.Podoplanin - an emerging cancer biomarker and therapeutic target.Trends in Malignant Glioma Monoclonal Antibody Therapy.Elevated expression of podoplanin and its clinicopathological, prognostic, and therapeutic values in squamous non-small cell lung cancer.Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.

P2860

Q26743903-1E2B9E6F-F627-4FA8-BE4E-B5AFFA3377C7 Q26795601-8989AAFC-0D54-41E8-A8D9-81F5A94126F8 Q28544645-F93B121C-157B-4732-9145-6E642F68C5FF Q33985502-F6EA2532-0FA1-4866-88C8-4DC2472E98D1 Q34982597-AADB021D-C5DD-4998-A2D8-0C5CD4883FD8 Q36546538-9B21D718-EB70-4272-BD4C-3075C038D6E0 Q36618989-E39E448F-5BA6-421C-A868-876C914F1167 Q36796918-84E27942-0E3E-42A3-84D1-4F87755FCE24 Q37154421-FC37B435-59C3-4E60-978F-601FE364F737 Q37562162-8387BF57-2752-4C5F-B8AB-1E3AF853ED5A Q37648097-F319F3E4-1BB6-4E0E-891F-6E77B19EDA53 Q37684156-52D95311-00BD-454F-883D-6EC87115DF3B Q37686698-917FD0A6-0156-47E5-8EBA-E3ADCD6AB428 Q38223220-C5FD403D-DCA8-4A90-ABCB-032A19E00643 Q38892678-F6053C13-7F01-452E-B8FD-680D457093DE Q38905443-B961D17E-543F-4ECD-B49A-A5577D283FB5 Q38930784-A6681967-26A4-40FC-87E1-765BE5A59175 Q38932619-3566FAA2-8F83-4476-B44D-3390E21B30B1 Q39028469-9324BE7C-C394-4825-B897-D75234A1BD02 Q41022992-A4672FAB-8A07-4764-8AE4-3557D78A95CA Q42267793-8A366BBD-037C-4FA9-83EB-D3BF98A97B32 Q42292310-8443DB94-A5C1-4A9D-821A-787CBFA3336B Q48367537-6779B757-5E47-4A1C-A5A5-8AA91DC9A243 Q52591453-D39AEC23-FAE9-4BEF-AEE0-D7A075BEC2D7 Q52724361-1044837B-355C-4B12-8959-686F47F8FCDF Q54942652-52073D71-9ADB-4595-9FD9-353AED3FA97B Q54964718-E33F6DBA-6ECC-45F6-B3F8-75435EC1AABF Q55363919-9B959495-B812-48FD-8058-5AEF7A5DFDAE

P2860

Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors.

http://www.wikidata.org/entity/Q37259430

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Recombinant anti-podoplanin (N ...... ent of malignant brain tumors.

@en

Recombinant anti-podoplanin

@nl

type

label

Recombinant anti-podoplanin (N ...... ent of malignant brain tumors.

@en

Recombinant anti-podoplanin

@nl

prefLabel

Recombinant anti-podoplanin (N ...... ent of malignant brain tumors.

@en

Recombinant anti-podoplanin

@nl

P1433

Q37259430-37B5111B-F8F4-496C-9AF2-49422037678A

P1476

Q37259430-6918F96F-9E17-4589-93A4-C42C9A8D6C1F

P2093

Q37259430-0AA33401-80BA-4577-961F-9C8AD3AC9ECD

Q37259430-3B5E3D8D-8999-4E76-9C79-157C0302740D

Q37259430-49255FC9-01AF-4296-B429-63942AC2FAD7

Q37259430-5708D865-9E0C-41D7-8A9B-5AB922A2DCBB

Q37259430-5A8E45DB-CCFA-472B-B40E-833228F7C082

Q37259430-708B907F-9011-4DAB-A679-889D817D16AA

Q37259430-7CB0E2B9-833A-4625-8456-F27AA641A3BD

Q37259430-A5D4F95C-07A4-4DCF-AE0D-C6EC75E53756

P2860

Q37259430-0AC470B3-B76D-4CD1-B0C5-8FF07F5A14AA

Q37259430-15598A9D-946F-4DBE-8152-1FF5688CDA77

Q37259430-19CA09B8-8E3C-4313-852C-FAA27475C31B

Q37259430-1E900A95-6A17-4169-876C-056DC01640FA

Q37259430-201D15DB-BE14-4208-A500-09806423FF5B

Q37259430-20B1D4E0-B808-42E4-BBBE-A2BFFFC17920

Q37259430-355198F9-F2F3-493A-85CF-5FFF64564895

Q37259430-3788A220-5355-4A8A-A2C0-6E1D314E1639

Q37259430-5DEB4041-6780-4064-A7BE-0C07D2F15365

Q37259430-69A33DCB-EAD0-4090-879E-18EF65AFA3FB

P304

Q37259430-DF07EE91-5B80-43D9-ACF0-43375E165874

P31

Q37259430-AFCDC1BB-976D-4437-8835-58F9CF6F6649

P356

Q37259430-3CEB591C-2DAF-4D34-A8E7-98759D8D6080

P433

Q37259430-AAA9EAD9-F728-4968-85D7-B1EFCD711486

P478

Q37259430-00A9487D-AF5E-4760-86E3-FADAE55B8625

P50

Q37259430-88A9B952-10EC-4223-8AC5-19A8266E89F5

P577

Q37259430-BEF80BCF-12A3-4BBC-ACC9-375ECC935086

P698

Q37259430-47F0F05E-C2E5-4A01-A50E-F3D8DA76AA5C

P932

Q37259430-C3F2A529-8EA4-4EEF-A58B-2F57194936DF

P356

P1433

International Journal of Cancer

P1476

Recombinant anti-podoplanin (N ...... ent of malignant brain tumors.

@en

P2093

Chien-Tsun Kuan

http://www.w3.org/2001/XMLSchema#string

Ira H Pastan

http://www.w3.org/2001/XMLSchema#string

Mika Kato Kaneko

http://www.w3.org/2001/XMLSchema#string

Scott E Szafranski

http://www.w3.org/2001/XMLSchema#string

Stephen T Keir

http://www.w3.org/2001/XMLSchema#string

Vidyalakshmi Chandramohan

http://www.w3.org/2001/XMLSchema#string

Xuhui Bao

http://www.w3.org/2001/XMLSchema#string

Yukinari Kato

http://www.w3.org/2001/XMLSchema#string

P2860

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis

Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton

Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression

Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain

T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema

Malignant astrocytic glioma: genetics, biology, and paths to treatment

Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition.

Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display.

Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

P304

2339-2348

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.27919

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

132

http://www.w3.org/2001/XMLSchema#string

P50

Darell D. Bigner

P577

2012-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23115013

http://www.w3.org/2001/XMLSchema#string

P932

3809846

http://www.w3.org/2001/XMLSchema#string